Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

NCT06694389 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2457

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
Influenza

Interventions

BIOLOGICAL: mRNA-1083
OTHER: Placebo
BIOLOGICAL: Licensed Influenza Vaccine
BIOLOGICAL: SARS-CoV-2 Vaccine

Sponsor

ModernaTX, Inc.